Targacept announces decision by AstraZeneca to advance AZD1446 in Alzheimer’s disease

Latest partnering news

AstraZeneca to acquire Ardea Biosciences for $1 billion (net of existing cash) including lead product lesinurad in Phase III development for gout  

23 April 2012

Conformetrix and AstraZeneca sign collaborative agreement

16 April 2012

AstraZeneca and Amgen announce collaboration to jointly develop and commercialise clinical-stage inflammation portfolio

2 April 2012

BioFocus and Argenta announce drug discovery collaboration with AstraZeneca in respiratory and inflammatory disease

14 March 2012

AstraZeneca Appoints Dr. Mike Poole to Lead New ‘Virtual’ Neuroscience Innovative Medicines Unit

7 February 2012

AstraZeneca and Karolinska Institutet PET Centre Announce Molecular Imaging Research Agreement

26 January 2012

AstraZeneca and IMS Health announce real-world evidence collaboration in Europe

11 January 2012

Targacept announces decision by AstraZeneca to advance AZD1446 in Alzheimer’s disease

5 January 2012

Dynavax and AstraZeneca agree to conduct toxicology studies for TLR-9 agonist for asthma

21 December 2011

AstraZeneca Enters into Option Agreement to Acquire New Class of Diabetes Assets from Prosidion

21 December 2011

AstraZeneca and Chi-Med enter into global collaboration to co-develop and commercialise novel cancer therapy

21 December 2011

AstraZeneca updates on olaparib and TC-5214 development programmes

20 December 2011